Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2008, p. 1846-1849, Vol. 52, No. 5
0066-4804/08/$08.00+0 doi:10.1128/AAC.01176-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units
Patricia J. Baudry,1,2*
Kim Nichol,2
Melanie DeCorby,1,2
Laura Mataseje,1,3
Michael R. Mulvey,1,3
Daryl J. Hoban,1,2 and
George G. Zhanel1,2
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3A 1R9, Manitoba, Canada,1
Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, R3A 1R9, Manitoba, Canada,2
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, R3E 3R2, Manitoba, Canada3
Received 6 September 2007/
Returned for modification 10 November 2007/
Accepted 9 February 2008
Resistance profiles were compared among 18 extended-spectrum-β-lactamase-producing (ESBL) and 27 acquired AmpC β-lactamase-producing Escherichia coli isolates collected from Canadian intensive care units from 2005 to 2006. ESBL-producing E. coli isolates were more likely to be gentamicin resistant (P < 0.03), fluoroquinolone resistant (P < 0.0001), and multidrug resistant (P < 0.0001) than AmpC-producing E. coli isolates.
* Corresponding author. Mailing address: Health Sciences Centre, Department of Clinical Microbiology, MS673-820 Sherbrook St., Winnipeg, Manitoba, Canada, R3A 1R9. Phone: (204) 787-4684. Fax: (204) 787-4699. E-mail:
trishbaudry{at}hotmail.com
Published ahead of print on 25 February 2008.
Antimicrobial Agents and Chemotherapy, May 2008, p. 1846-1849, Vol. 52, No. 5
0066-4804/08/$08.00+0 doi:10.1128/AAC.01176-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A.
(2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother
64: 824-828
[Abstract]
[Full Text]
-
Mataseje, L. F., Neumann, N., Crago, B., Baudry, P., Zhanel, G. G., Louie, M., Mulvey, M. R., and the ARO Water Study Group,
(2009). Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006. Antimicrob. Agents Chemother.
53: 3126-3130
[Abstract]
[Full Text]